A nutraceutical formulation used to unblock receptors is disclosed herein. The nutraceutical formulation used to therapeutically treat humans includes arachidonic acid, docosahexaenoic acid (DHA), echinacea, kaempferol, coffee fruit, and probiotics.

A nutraceutical formulation used to unblock receptors is disclosed herein. The nutraceutical formulation used to therapeutically treat humans includes arachidonic acid, docosahexaenoic acid (DHA), echinacea, kaempferol, coffee fruit, and probiotics.

A botanical extract that exhibits antioxidant activity, wherein the botanical extract is at least an extract from the genus Anacardium.

A botanical extract that exhibits antioxidant activity, wherein the botanical extract is at least an extract from the genus Anacardium.

A method for treating sleep disturbance according to an embodiment of the present disclosure includes administering to a subject in need thereof a composition including saponarin of Chemical Formula 1, a salt thereof acceptable for use in food, or a hydrate thereof as an effective component: In an animal model with lack of sleep caused by caffeine, saponarin of the present invention restores the travel distance, mobility time, mobility frequency, and immobility time to normal as well as increases the mRNA expression of neuropeptide Y, cholecystokinin, and GABA A α1 receptor, thereby alleviating sleep disturbance. Therefore, the saponarin of the present invention can be advantageously used as a raw material for a functional health food or a pharmaceutical product for preventing, alleviating, or treating sleep disturbance.

A method for treating sleep disturbance according to an embodiment of the present disclosure includes administering to a subject in need thereof a composition including saponarin of Chemical Formula 1, a salt thereof acceptable for use in food, or a hydrate thereof as an effective component: In an animal model with lack of sleep caused by caffeine, saponarin of the present invention restores the travel distance, mobility time, mobility frequency, and immobility time to normal as well as increases the mRNA expression of neuropeptide Y, cholecystokinin, and GABA A α1 receptor, thereby alleviating sleep disturbance. Therefore, the saponarin of the present invention can be advantageously used as a raw material for a functional health food or a pharmaceutical product for preventing, alleviating, or treating sleep disturbance.

Isoflavone-supplemented milk replacers fed to young animals during a pre-weaning provides isoflavones in the milk replacer at a level of about 700 mg per kilogram of the milk replacer, and/or provides about 450 mg of the supplemental isoflavone in at least about 1.5 pounds of the milk replacer by dry weight such that the animal ingests this amount of the isoflavone per day, and/or provides in the milk replacer at least about 50 mg of isoflavone per pound of the animal’s birth weight is ingested per day. In response to ingesting the isoflavone-supplemented milk replacer, the young animal experiences improved performance.

Isoflavone-supplemented milk replacers fed to young animals during a pre-weaning provides isoflavones in the milk replacer at a level of about 700 mg per kilogram of the milk replacer, and/or provides about 450 mg of the supplemental isoflavone in at least about 1.5 pounds of the milk replacer by dry weight such that the animal ingests this amount of the isoflavone per day, and/or provides in the milk replacer at least about 50 mg of isoflavone per pound of the animal’s birth weight is ingested per day. In response to ingesting the isoflavone-supplemented milk replacer, the young animal experiences improved performance.

The present invention pertains to high protein, micellar casein-containing nutritional liquids enriched with catechin-compounds and a method of their production. The invention particularly provides such high protein liquids having a reduced viscosity and a reduced tendency to cold-gelation.

The present invention pertains to high protein, micellar casein-containing nutritional liquids enriched with catechin-compounds and a method of their production. The invention particularly provides such high protein liquids having a reduced viscosity and a reduced tendency to cold-gelation.